Verona Pharma plc Verona Pharma plc

Verona Pharma plc

VRNA

株式のランク #2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
株価
$106.91
最終同期: 2025-10-07
時価総額
$9.09B
変化(1日)
0.00%
変化(1年)
0.00%
国
GB
取引 Verona Pharma plc (VRNA)

カテゴリー

Healthcare
Verona Pharma plc(VRNA)のP/S比率
October 2026 時点のP/S比率 TTM: 2.15K
Verona Pharma plc の最新の財務報告および株価によると、現在のP/S比率(TTM)は 2.15K です。2023 年末時点でのP/S比率は 0.00 でした。
Verona Pharma plc の P/S 比率の履歴(2005 ~ 2026)
各年末時点のP/S比率
年 P/S比率 変化
2026 (TTM) 2.15K 1,849.31%
2024 110.41 0.00%
2023 0.00 -100.00%
2022 3.77K 37,827.00%
2021 9.94 0.00%
2020 0.00 -100.00%
2019 24.28K -32.01%
2018 35.71K 65,523.71%
2017 54.42 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
10.02 -99.53%
US
40.55 -98.12%
US
3.96 -99.82%
AU
- -
CH
10.15 -99.53%
NL